Top

Published in:

Open Access 01-12-2014 | Research article

Levels of brain natriuretic peptide are associated with peripheral arterial disease in subjects with type-2 diabetes mellitus

Authors: Qi-hui Jin, Wan-lan Ye, Huai-hong Chen, Xiao-jun He, Tian-lang Li, Qiang Liu, Liang Zhong, Lei Xu, Chun-mao Han

Published in: BMC Endocrine Disorders | Issue 1/2014

Abstract

Background

The effects of brain natriuretic peptide (BNP) on the risk of cardiovascular disease and atherosclerosis have been studied. However, little information is available regarding peripheral arterial disease (PAD), particularly among subjects with type-2 diabetes mellitus (T2DM). The aim of our study was to assess the potential relationship between BNP levels and PAD among T2DM patients.

Methods

The study cohort was 507 T2DM outpatients in which BNP levels were measured. Cross-sectional associations between BNP levels (in tertiles) and PAD were examined.

Results

Compared withT2DM patients without PAD, BNP levels were markedly higher in patients with PAD (p = 0.001). Correlation analyses showed that the BNP level was negatively correlated with the ankle–brachial index (r = −0.453, p = 0.033). At a cutoff value of 78.2 pg/ml, the BNP level showed a sensitivity of 71.9%, a specificity of 68.1%, and a positive predictive value of 84.3% for a diagnosis of PAD. The area under the receiver-operating characteristic curve increased significantly if BNP levels were incorporated into a predictive model of the potential risk factors for PAD (0.85 vs 0.81, p = 0.029).

Conclusions

BNP is a potential and promising biomarker for PAD screening in T2DM patients.

Available only for authorised users

American Diabetes Association: Peripheral arterial disease in people with diabetes. Diabetes Care. 2003, 26: 3333-3341.CrossRef

Wattanakit K, Folsom AR, Selvi NE, Weatherley BD, Pankow JS, Brancati FL, Hirsch AT: Risk factors for peripheral arterial disease incidence in persons with diabetes: The Athe rosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2005, 180: 389-397. 10.1016/j.atherosclerosis.2004.11.024.CrossRefPubMed

Walters DP, Gatling W, Mullee MA, Hill RD: The prevalence, detection, and epidemiological correlates of peripheral vascular disease: a comparison of diabetic and non-diabetic subjects in an English community. Diabet Med. 1992, 9: 710-715. 10.1111/j.1464-5491.1992.tb01878.x.CrossRefPubMed

Wannamethee SG, Welsh P, Lowe GD, Gudnason V, Di Angelantonio E, Lennon L, Rumley A, Whincup PH, Sattar N: N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol. 2011, 58: 56-64. 10.1016/j.jacc.2011.02.041.CrossRefPubMed

Ashley KE, Galla JM, Nicholls SJ: Brain natriuretic peptides as biomarkers for atherosclerosis. Prev Cardiol. 2008, 11: 172-176. 10.1111/j.1751-7141.2008.08578.x.CrossRefPubMed

Svensson P, de Faire U, Niklasson U, Hansson LO, Ostergren J: Plasma NT-pro-BNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood Press. 2005, 14: 99-106. 10.1080/08037050510008931.CrossRefPubMed

Dieplinger B, Poelz W, Haltmayer M, Mueller T: Association of adiponectin and aminoterminal proBNP in peripheral arterial disease. Clin Chim Acta. 2007, 377: 192-197. 10.1016/j.cca.2006.09.022.CrossRefPubMed

Mueller T, Dieplinger B, Poelz W, Endler G, Wagner OF, Haltmayer M: Aminoterminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the linz peripheral arterial disease study. Clin Chem. 2009, 55: 68-77.CrossRefPubMed

Ye Z, Ali Z, Klee GG, Mosley TH, Kullo IJ: Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease. Am J Hypertens. 2013, 26: 495-502. 10.1093/ajh/hps073.CrossRefPubMedPubMedCentral

10.

Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K, Blankenberg S: Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One. 2010, 5: e10100-10.1371/journal.pone.0010100.CrossRefPubMedPubMedCentral

11.

Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, Meirhaeghe A, Khaw KT, Sattar N, Langenberg C, Wareham NJ: Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011, 8: e1001112-10.1371/journal.pmed.1001112.CrossRefPubMedPubMedCentral

12.

Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ: Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009, 41: 348-353. 10.1038/ng.328.CrossRefPubMedPubMedCentral

13.

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003, 26: S5-S20.CrossRef

14.

Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, White CJ, White J, White RA, Antman EM, Smith SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease. Circulation. 2006, 113: e463-e654.CrossRefPubMed

15.

Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, American Diabetes Association: Diabetic nephropathy. Diabetes Care. 2003, 26: S94-S98.CrossRefPubMed

16.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013, 34: 2159-2219.CrossRefPubMed

17.

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012, 33: 1787-1847.CrossRefPubMed

18.

Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association: Diabetic neuropathies: a statement by the American diabetes association. Diabetes Care. 2005, 28: 956-962. 10.2337/diacare.28.4.956.CrossRefPubMed

19.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.CrossRef

20.

Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA, Mukamal KJ: Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012, 308: 1660-1667. 10.1001/jama.2012.13415.CrossRefPubMedPubMedCentral

21.

Jude EB, Eleftheriadou I, Tentolouris N: Peripheral arterial disease in diabetes – a review. Diabet Med. 2010, 27: 4-14. 10.1111/j.1464-5491.2009.02866.x.CrossRefPubMed

22.

Aronow WS, Ahn C, Weiss MB, Babu S: Relation of increased hemoglobin A(1c) levels to severity of peripheral arterial disease in patients with diabetes mellitus. Am J Cardiol. 2007, 99: 1468-1469. 10.1016/j.amjcard.2006.12.085.CrossRefPubMed

23.

Görmüş U, Ozmen D, Ozmen B, Parildar Z, Ozdoğan O, Mutaf I, Bayindir O: Serum N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and homocysteine levels in type 2 diabetic patients with asymptomatic left ventricular diastolic dysfunction. Diabetes Res Clin Pract. 2010, 87: 51-56. 10.1016/j.diabres.2009.10.010.CrossRefPubMed

24.

Phelan D, Watson C, Martos R, Collier P, Patle A, Donnelly S, Ledwidge M, Baugh J, McDonald K: Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One. 2012, 7: e49259-10.1371/journal.pone.0049259.CrossRefPubMedPubMedCentral

25.

Chen X, Zhan X, Chen M, Lei H, Wang Y, Wei D, Jiang X: The prognostic value of combined NT-pro-BNP levels and NIHSS scores in patients with acute ischemic stroke. Intern Med. 2012, 51: 2887-2892. 10.2169/internalmedicine.51.8027.CrossRefPubMed

26.

Takahashi T, Nakamura M, Onoda T, Ohsawa M, Tanno K, Itai K, Sakata K, Sakuma M, Tanaka F, Makita S, Yoshida Y, Ogawa A, Kawamura K, Okayama A: Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a community-based longitudinal study. Atherosclerosis. 2009, 207: 298-303. 10.1016/j.atherosclerosis.2009.04.029.CrossRefPubMed

27.

Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK: Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 2008, 3: 1644-1651. 10.2215/CJN.00850208.CrossRefPubMedPubMedCentral

28.

Oztekin S, Karakurt O, Yazıhan N, Unal I: Relationship of brain natriuretic peptide with metabolic syndrome parameters: an observational study. Anadolu Kardiyol Derg. 2011, 11: 678-684.PubMed

29.

Omland T: Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Crit Care Med. 2008, 36: S17-S27. 10.1097/01.CCM.0000296266.74913.85.CrossRefPubMed

30.

Issa VS, Taniguchi LU, Park M, Cruz LM, Bocchi EA, Velasco IT, Soriano F: Positive end-expiratory pressure and renal function influence B-type natriuretic peptide in patients with severe sepsis and septic shock. Arq Bras Cardiol. 2008, 91: 107-112.CrossRefPubMed

31.

Clerico A, Giannoni A, Vittorini S, Passino C: Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 2011, 301: H12-H20. 10.1152/ajpheart.00226.2011.CrossRefPubMed

32.

Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A: Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol. 2008, 52: 1736-1742. 10.1016/j.jacc.2008.07.060.CrossRefPubMedPubMedCentral

33.

Fan J, Jouni H, Khaleghi M, Bailey KR, Kullo IJ: Serum N-terminal pro-B-type natriuretic peptide levels are associated with functional capacity in patients with peripheral arterial disease. Angiology. 2012, 63: 435-442. 10.1177/0003319711423095.CrossRefPubMed

34.

Keda M, Kohno M, Yasunari K, Yokokawa K, Horio T, Ueda M, Morisaki N, Yoshikawa J: Natriuretic peptide family as a novel antimigration factor of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997, 17: 731-736.CrossRef

35.

Chen H, Levine YC, Golan DE, Michel T, Lin AJ: Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilatorstimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem. 2008, 283: 4439-4447. 10.1074/jbc.M709439200.CrossRefPubMed

36.

Park K, Itoh H, Yamahara K, Sone M, Miyashita K, Oyamada N, Sawada N, Taura D, Inuzuka M, Sonoyama T, Tsujimoto H, Fukunaga Y, Tamura N, Nakao K: Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology. 2008, 149: 483-491. 10.1210/en.2007-1094.CrossRefPubMed

37.

Shmilovich H, Ben-Shoshan J, Tal R, Afek A, Barshack I, Maysel-Auslander S, Harats D, Keren G, George J: B-type natriuretic peptide enhances vasculogenesis by promoting number and func-tional properties of early endothelial progenitor cells. Tissue Eng Part A. 2009, 15: 2741-2749. 10.1089/ten.tea.2008.0414.CrossRefPubMed

38.

Talha S, Bouitbir J, Charles AL, Zoll J, Goette-Di Marco P, Meziani F, Piquard F, Geny B: Pretreatment with brain natriuretic peptide reduces skeletal muscle mitochondrial dysfunction and oxidative stress after ischemia-reperfusion. J Appl Physiol. 2013, 114: 172-179. 10.1152/japplphysiol.00239.2012.CrossRefPubMed

39.

Kuhn M, Völker K, Schwarz K, Carbajo-Lozoya J, Flögel U, Jacoby C, Stypmann J, van Eickels M, Gambaryan S, Hartmann M, Werner M, Wieland T, Schrader J, Baba HA: The natriuretic peptide/guanylyl cyclase–a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest. 2009, 119: 2019-2030. 10.1172/JCI37430.CrossRefPubMedPubMedCentral

40.

Tokudome T, Kishimoto I, Yamahara K, Osaki T, Minamino N, Horio T, Sawai K, Kawano Y, Miyazato M, Sata M, Kohno M, Nakao K, Kangawa K: Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-a, a receptor for atrial and brain natriuretic peptides. Arterioscler Thromb Vasc Biol. 2009, 29: 1516-1521.CrossRefPubMed

41.

Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Simari RD, Burnett JC: Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol. 2000, 35: 796-801. 10.1016/S0735-1097(99)00593-8.CrossRefPubMed

42.

Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer CD, Pinach S, Manzo M, Loiacono M, Tricarico M, Mengozzi G, Witte DR, Fuller JH, Perin PC, Bruno G: NH2-terminal probrain natriuretic peptide is associated with diabetes complications in the EURODIAB Prospective Complications Study: the role of tumor necrosis factor-α. Diabetes Care. 2012, 35: 1931-1936. 10.2337/dc12-0089.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6823/14/27/prepub

Title: Levels of brain natriuretic peptide are associated with peripheral arterial disease in subjects with type-2 diabetes mellitus
Authors: Qi-hui Jin
Wan-lan Ye
Huai-hong Chen
Xiao-jun He
Tian-lang Li
Qiang Liu
Liang Zhong
Lei Xu
Chun-mao Han
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Endocrine Disorders / Issue 1/2014
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/1472-6823-14-27

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Levels of brain natriuretic peptide are associated with peripheral arterial disease in subjects with type-2 diabetes mellitus

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

A pilot study: the development of a culturally tailored Malaysian Diabetes Education Module (MY-DEMO) based on the Health Belief Model

Increased waist circumference is independently associated with hypothyroidism in Mexican Americans: replicative evidence from two large, population-based studies

1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma

Design of the e-Vita diabetes mellitus study: effects and use of an interactive online care platform in patients with type 2 diabetes (e-VitaDM-1/ZODIAC-40)

Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligand-induced repression of the human glucocorticoid receptor

Association of calcaneal quantitative ultrasound parameters with metabolic syndrome in middle-aged and elderly Chinese: a large population-based cross-sectional study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page